Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 1
2013 7
2014 5
2015 6
2016 5
2017 5
2018 15
2019 9
2020 16
2021 18
2022 32
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K. Takahashi H, et al. Among authors: kessoku t. Hepatol Commun. 2022 Jan;6(1):120-132. doi: 10.1002/hep4.1696. Epub 2021 Jun 17. Hepatol Commun. 2022. PMID: 34558835 Free PMC article. Clinical Trial.
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Front Endocrinol (Lausanne). 2021 Oct 29;12:770986. doi: 10.3389/fendo.2021.770986. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34777261 Free PMC article. Review.
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Kawada N, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Kamada Y, Takahashi H, Sumida Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Fujii H, et al. Among authors: kessoku t. Hepatol Res. 2023 Nov;53(11):1059-1072. doi: 10.1111/hepr.13947. Epub 2023 Aug 28. Hepatol Res. 2023. PMID: 37537735
Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Tomeno W, et al. Among authors: kessoku t. Expert Opin Emerg Drugs. 2013 Sep;18(3):279-90. doi: 10.1517/14728214.2013.811232. Epub 2013 Jul 13. Expert Opin Emerg Drugs. 2013. PMID: 23848366 Review.
Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs.
Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, Honda K, Kobayashi T, Nogami A, Kato T, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Sakamoto Y, Yoneda M, Saito S, Nakajima A. Tomeno W, et al. Among authors: kessoku t. Diagnostics (Basel). 2020 Nov 7;10(11):912. doi: 10.3390/diagnostics10110912. Diagnostics (Basel). 2020. PMID: 33171865 Free PMC article. Review.
[Gut microbiota and nonalcoholic steatohepatitis].
Kessoku T, Imajo K, Kobayashi T, Honda Y, Ogawa Y, Yoneda M, Saito S, Nakajima A. Kessoku T, et al. Nihon Yakurigaku Zasshi. 2018;152(4):187-193. doi: 10.1254/fpj.152.187. Nihon Yakurigaku Zasshi. 2018. PMID: 30298840 Japanese.
[Gut microbiota and NASH].
Nakajima A, Honda Y, Kessoku T, Ogawa Y, Imajo K. Nakajima A, et al. Among authors: kessoku t. Nihon Shokakibyo Gakkai Zasshi. 2015 Nov;112(11):1966-72. doi: 10.11405/nisshoshi.112.1966. Nihon Shokakibyo Gakkai Zasshi. 2015. PMID: 26537323 Review. Japanese. No abstract available.
128 results